The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and …

Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

Objective: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist)
in improving 28-day survival in sepsis patients with features of macrophage activation …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of
galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit …

Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…

Objective To assess the effects of the B lymphocyte stimulator (BLyS)–specific inhibitor
belimumab on immunologic biomarkers, including B cell and T cell populations, and …

Cytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of
respiratory failure, but timing and patient selection are key.

Systemic lupus erythematosus (SLE) is an autoimmune disease with known genetic,
epigenetic, and environmental risk factors. To assess the role of DNA methylation in SLE, we …